Abstract
As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed. The anti-malarial artesunate was previously shown to exert a profound cytotoxic effect on various tumor cell lines including those derived from glioblastoma. In the current study, we sought to examine the antiproliferative effect of a combination of temozolomide and artesunate on two different established human glioblastoma cell lines. The IC50 and IC25 were determined for temozolomide and artesunate in U87MG and A172 glioblastoma cell lines after 144 h of continuous drug exposure. The antiproliferative effect of combining both agents at IC50/IC50 and IC25/IC25 was determined by a cell viability assay. Moreover, necrosis and apoptosis were analyzed by annexin V/PI staining and flow cytometric analysis. In addition, cytostatic effects were examined by carboxyfluorescein diacetate succinimidyl ester staining and subsequent flow cytometry. In both glioblastoma cell lines, artesunate was found to enhance the antiproliferative effect exerted by temozolomide. Moreover, artesunate acted in concert with temozolomide in terms of cytostatic and necrotizing effects. These observations suggest that a combination of artesunate and temozolomide might result in increased cytotoxicity in glioblastoma.
Keywords: Artesunate, combination therapy, cytostasis, glioblastoma, necrosis, temozolomide.
Anti-Cancer Agents in Medicinal Chemistry
Title:Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines
Volume: 14 Issue: 2
Author(s): Georg Karpel-Massler, Mike-Andrew Westhoff, Richard E. Kast, Annika Dwucet, Lisa Nonnenmacher, C. Rainer Wirtz, Klaus-Michael Debatin and Marc-Eric Halatsch
Affiliation:
Keywords: Artesunate, combination therapy, cytostasis, glioblastoma, necrosis, temozolomide.
Abstract: As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed. The anti-malarial artesunate was previously shown to exert a profound cytotoxic effect on various tumor cell lines including those derived from glioblastoma. In the current study, we sought to examine the antiproliferative effect of a combination of temozolomide and artesunate on two different established human glioblastoma cell lines. The IC50 and IC25 were determined for temozolomide and artesunate in U87MG and A172 glioblastoma cell lines after 144 h of continuous drug exposure. The antiproliferative effect of combining both agents at IC50/IC50 and IC25/IC25 was determined by a cell viability assay. Moreover, necrosis and apoptosis were analyzed by annexin V/PI staining and flow cytometric analysis. In addition, cytostatic effects were examined by carboxyfluorescein diacetate succinimidyl ester staining and subsequent flow cytometry. In both glioblastoma cell lines, artesunate was found to enhance the antiproliferative effect exerted by temozolomide. Moreover, artesunate acted in concert with temozolomide in terms of cytostatic and necrotizing effects. These observations suggest that a combination of artesunate and temozolomide might result in increased cytotoxicity in glioblastoma.
Export Options
About this article
Cite this article as:
Karpel-Massler Georg, Westhoff Mike-Andrew, Kast E. Richard, Dwucet Annika, Nonnenmacher Lisa, Wirtz Rainer C., Debatin Klaus-Michael and Halatsch Marc-Eric, Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (2) . https://dx.doi.org/10.2174/18715206113136660340
DOI https://dx.doi.org/10.2174/18715206113136660340 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Poly(lactic acid)-poly(ethylene oxide) Block Copolymers: New Directions in Self-Assembly and Biomedical Applications
Current Medicinal Chemistry Dihydropyrimidine Dehydrogenase Genotyping and Phenotyping for 5- Fluorouracil Dysmetabolism: Moving Towards Personalized Chemotherapy in Patients with Cancer
Current Pharmacogenomics and Personalized Medicine The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Topical Melatonin Niosome Gel for the Treatment of 5-FU-Induced Oral Mucositis in Mice
Current Drug Delivery Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel
Current Medicinal Chemistry Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in Nano-Drug Delivery Systems Loaded by Phytochemicals for Wound Healing
Mini-Reviews in Medicinal Chemistry Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Delta Np63 alpha – Responsive microRNA Modulate the Expression of Metabolic Enzymes
Current Pharmaceutical Biotechnology Physicochemical Properties that Determine Cellular Transport of Nanocarriers In Vitro and In Vivo
Current Organic Chemistry The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry The Metastatic Process: Methodological Advances and Pharmacological Challenges
Current Medicinal Chemistry Chemotherapeutic Targeting of Cell Death Pathways
Anti-Cancer Agents in Medicinal Chemistry Poly (Lactic-co-Glycolic Acid) & Tocopheryl Polyethylene Glycol Succinate Nanoparticles for the Treatment of Different Brain Cancers
Anti-Cancer Agents in Medicinal Chemistry Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology COX-2 and Colorectal Cancer
Current Pharmaceutical Design Ligand-Based Drug Design of Novel MARK-3 Inhibitors in Cancer
Current Bioactive Compounds